Clinical Research Directory
Browse clinical research sites, groups, and studies.
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis
Sponsor: Institute of Liver and Biliary Sciences, India
Summary
Chronic liver disease is a growing health concern, with limited access to liver transplants. This study addresses the urgent need for alternatives by exploring regenerative therapies, like G-CSF, to boost the liver's natural repair. The goal is to develop safe, effective, and accessible treatments for patients who cannot undergo transplant.
Official title: National Collaborative Centre for Hepatic Regenerative Medicine(NC-CHRM): To Study the Efficacy of Single vs Repeated Cycle of GCSF+ Darbepoetin in Long Term Transplant Free Management of Patient With Early Decompensated Cirrhosis
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
110
Start Date
2025-09
Completion Date
2031-12
Last Updated
2025-08-20
Healthy Volunteers
No
Conditions
Interventions
Gcsf
G-CSF will be given at a dose of 5 μg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30
Darbepoetin
Darbepoetin will be given s/c at dose of 40mcg once a week for 1 month
Standard Medical Treatment
Standard Medical Treatment
Locations (1)
Institute of Liver & Biliary Sciences
New Delhi, India